256 related articles for article (PubMed ID: 12694869)
21. DNA damage persistence as determinant of tumor sensitivity to the combination of Topo I inhibitors and telomere-targeting agents.
Biroccio A; Porru M; Rizzo A; Salvati E; D'Angelo C; Orlandi A; Passeri D; Franceschin M; Stevens MF; Gilson E; Beretta G; Zupi G; Pisano C; Zunino F; Leonetti C
Clin Cancer Res; 2011 Apr; 17(8):2227-36. PubMed ID: 21355072
[TBL] [Abstract][Full Text] [Related]
22. Dynamic regulation of Rad51 by E2F1 and p53 in prostate cancer cells upon drug-induced DNA damage under hypoxia.
Wu M; Wang X; McGregor N; Pienta KJ; Zhang J
Mol Pharmacol; 2014 Jun; 85(6):866-76. PubMed ID: 24627085
[TBL] [Abstract][Full Text] [Related]
23. Potentiation of cytotoxicity of topoisomerase i poison by concurrent and sequential treatment with the checkpoint inhibitor UCN-01 involves disparate mechanisms resulting in either p53-independent clonogenic suppression or p53-dependent mitotic catastrophe.
Tse AN; Schwartz GK
Cancer Res; 2004 Sep; 64(18):6635-44. PubMed ID: 15374978
[TBL] [Abstract][Full Text] [Related]
24. Characterization of protein kinase chk1 essential for the cell cycle checkpoint after exposure of human head and neck carcinoma A253 cells to a novel topoisomerase I inhibitor BNP1350.
Yin MB; Guo B; Vanhoefer U; Azrak RG; Minderman H; Frank C; Wrzosek C; Slocum HK; Rustum YM
Mol Pharmacol; 2000 Mar; 57(3):453-9. PubMed ID: 10692484
[TBL] [Abstract][Full Text] [Related]
25. Sensitization to gimatecan-induced apoptosis by tumor necrosis factor-related apoptosis inducing ligand in prostate carcinoma cells.
Perego P; Ciusani E; Gatti L; Carenini N; Corna E; Zunino F
Biochem Pharmacol; 2006 Mar; 71(6):791-8. PubMed ID: 16438941
[TBL] [Abstract][Full Text] [Related]
26. Camptothecins and topoisomerase I: a foot in the door. Targeting the genome beyond topoisomerase I with camptothecins and novel anticancer drugs: importance of DNA replication, repair and cell cycle checkpoints.
Pommier Y
Curr Med Chem Anticancer Agents; 2004 Sep; 4(5):429-34. PubMed ID: 15379698
[TBL] [Abstract][Full Text] [Related]
27. Drug-induced apoptosis is not necessarily dependent on macromolecular synthesis or proliferation in the p53-negative human prostate cancer cell line PC-3.
Borner MM; Myers CE; Sartor O; Sei Y; Toko T; Trepel JB; Schneider E
Cancer Res; 1995 May; 55(10):2122-8. PubMed ID: 7743512
[TBL] [Abstract][Full Text] [Related]
28. Influence of G2 arrest on the cytotoxicity of DNA topoisomerase inhibitors toward human carcinoma cells with different p53 status.
Bozko P; Larsen AK; Raymond E; Skladanowski A
Acta Biochim Pol; 2002; 49(1):109-19. PubMed ID: 12136930
[TBL] [Abstract][Full Text] [Related]
29. Beta-lapachone-mediated apoptosis in human promyelocytic leukemia (HL-60) and human prostate cancer cells: a p53-independent response.
Planchon SM; Wuerzberger S; Frydman B; Witiak DT; Hutson P; Church DR; Wilding G; Boothman DA
Cancer Res; 1995 Sep; 55(17):3706-11. PubMed ID: 7641180
[TBL] [Abstract][Full Text] [Related]
30. Intracellular accumulation and DNA damage persistence as determinants of human squamous cell carcinoma hypersensitivity to the novel camptothecin ST1968.
Pisano C; Zuco V; De Cesare M; Benedetti V; Vesci L; Foderà R; Bucci F; Aulicino C; Penco S; Carminati P; Zunino F
Eur J Cancer; 2008 Jun; 44(9):1332-40. PubMed ID: 18445521
[TBL] [Abstract][Full Text] [Related]
31. Synergistic antitumor effect between vorinostat and topotecan in small cell lung cancer cells is mediated by generation of reactive oxygen species and DNA damage-induced apoptosis.
Bruzzese F; Rocco M; Castelli S; Di Gennaro E; Desideri A; Budillon A
Mol Cancer Ther; 2009 Nov; 8(11):3075-87. PubMed ID: 19887547
[TBL] [Abstract][Full Text] [Related]
32. Effects of drug efflux proteins and topoisomerase I mutations on the camptothecin analogue gimatecan.
Gounder MK; Nazar AS; Saleem A; Pungaliya P; Kulkarni D; Versace R; Rubin EH
Invest New Drugs; 2008 Jun; 26(3):205-13. PubMed ID: 17943230
[TBL] [Abstract][Full Text] [Related]
33. Low-level resistance to camptothecin in a human small-cell lung cancer cell line without reduction in DNA topoisomerase I or drug-induced cleavable complex formation.
Sorensen M; Sehested M; Christensen IJ; Larsen JK; Jensen PB
Br J Cancer; 1998 Jun; 77(12):2152-61. PubMed ID: 9649127
[TBL] [Abstract][Full Text] [Related]
34. Caffeine prevents apoptosis and cell cycle effects induced by camptothecin or topotecan in HL-60 cells.
Traganos F; Kapuscinski J; Gong J; Ardelt B; Darzynkiewicz RJ; Darzynkiewicz Z
Cancer Res; 1993 Oct; 53(19):4613-8. PubMed ID: 8402636
[TBL] [Abstract][Full Text] [Related]
35. Differences in induction of p53, p21WAF1 and apoptosis in relation to cell cycle phase of MCF-7 cells treated with camptothecin.
Deptala A; Li X; Bedner E; Cheng W; Traganos F; Darzynkiewicz Z
Int J Oncol; 1999 Nov; 15(5):861-71. PubMed ID: 10536167
[TBL] [Abstract][Full Text] [Related]
36. Cell cycle disturbances and apoptosis induced by topotecan and gemcitabine on human lung cancer cell lines.
Tolis C; Peters GJ; Ferreira CG; Pinedo HM; Giaccone G
Eur J Cancer; 1999 May; 35(5):796-807. PubMed ID: 10505042
[TBL] [Abstract][Full Text] [Related]
37. Topotecan-triggered degradation of topoisomerase I is p53-dependent and impacts cell survival.
Tomicic MT; Christmann M; Kaina B
Cancer Res; 2005 Oct; 65(19):8920-6. PubMed ID: 16204064
[TBL] [Abstract][Full Text] [Related]
38. Role of wild-type p53 in the enhancement of camptothecin cytotoxicity against human prostate tumor cells.
Arah IN; Song K; Seth P; Cowan KH; Sinha BK
Anticancer Res; 1998; 18(3A):1845-9. PubMed ID: 9673414
[TBL] [Abstract][Full Text] [Related]
39. A novel 7-modified camptothecin analog overcomes breast cancer resistance protein-associated resistance in a mitoxantrone-selected colon carcinoma cell line.
Perego P; De Cesare M; De Isabella P; Carenini N; Beggiolin G; Pezzoni G; Palumbo M; Tartaglia L; Pratesi G; Pisano C; Carminati P; Scheffer GL; Zunino F
Cancer Res; 2001 Aug; 61(16):6034-7. PubMed ID: 11507048
[TBL] [Abstract][Full Text] [Related]
40. Antiangiogenic potential of camptothecin and topotecan.
Clements MK; Jones CB; Cumming M; Daoud SS
Cancer Chemother Pharmacol; 1999; 44(5):411-6. PubMed ID: 10501915
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
